Dressing for treating skin conditions and relieving symptoms of skin conditions causing blood protein exudation

FIELD: medicine.

SUBSTANCE: what is described is a dressing for treating skin conditions and relieving symptoms of skin conditions accompanying blood protein exudation, or for absorbing blood proteins transuding onto the skin.

EFFECT: using the dressing for clearance of waste proteins secreted onto the skin.

8 cl, 22 dwg, 7 ex

 

The technical field to which the invention relates.

The present invention relates to a bandage for the treatment of skin diseases and relieve symptoms of skin diseases, in which there is exudation of blood proteins, or for absorption of blood proteins that are secreted onto the skin.

The level of technology

A new theory of the causes of atopic diseases

Various factors, such as genetic factors, pollen, dust mites, chemicals, such as formaldehyde, and westernized food are considered as the causes that lead to atopic disease. However, the exact cause of the disease is still not clear. As immunological effects in atopic diseases have unique characteristics, such as the activation of Th1 cells during infection of the epidermis, and also the high activity of Th2 cells as one of the phenomena that occur during continuous exposure of large antigens, such as antigens in the liver parasites, or as a mechanism of immune-modulating control. The present invention does not place emphasis on the unique immunological phenomena occurring in atopic diseases. However, in the present invention, it is assumed that the phenomenon of penetration of blood proteins leaking from the blood vessels of vutcani of the skin due to the imbalance of metabolism or metabolic disorders in the body, represents the beginning and the root cause of atopic disease. Thus, suppose that the immune response generated in atopic diseases are caused by exudation of blood proteins. Based on the above consideration, the present invention attempts to solve these problems. In addition, it is also believed that psoriasis is caused by exudation of blood proteins, and thus, the present invention proposes a new drug for the treatment of psoriasis based on the above reasons.

Until the 1980's (before the 1970-ies in the United States or the United Kingdom), the incidence of atopic diseases was not very high, and they never worked as a social problem. However, since the late 1980's, the incidence of atopic diseases has increased dramatically, and according to the latest data, one in five primary school students has symptoms of atopic disease. Accordingly, atopic disease has become a serious social problem. The comparison between the 1970s and 2000s shows that air pollution is significantly decreased in comparison with the pollution 20-30 years ago, due to the prohibition of the use of leaded petrol, strict government regulation of automobile emissions, the introduction of public transport use is it natural gas, regulation of dust from the plants operation, policy group (organization of industrial complexes enterprises which emit pollutants, etc. For this reason I believe that the incidence of atopic diseases is not increased because the present environment and conditions.

Modern accommodations have a box much larger than the dwellings of the 1970-ies, and construction has changed in such a way that inside people get much more sunlight. Vacuum cleaners with microfilters are becoming more and more common, used washing machine with a bactericidal function, and detergents are more concentrated and diverse. Dust the clamp becomes more difficult to exist in modern conditions than in previous years. Thus, it is difficult to explain the relationship between the frequency of atopic diseases and dust mites. Unlike the city, in rural areas there is a large variety of herbs. The concentration of pollen is much more in rural areas compared to the city. However, the frequency of atopic diseases in the city is higher than in rural areas. There is no relationship between the concentration of pollen and frequency of atopic diseases. Thus, it is difficult to consider the ka pollen is the cause of atopic disease.

Things have changed markedly in urban culture compared to the 1970s, include suppliers of food products, various fast food restaurants, convenient public transport, private cars, etc. in Addition, since the mid-1980s the most noticeable change is the change of food and, especially, oils for cooking (soybean oil, corn oil, olive oil, grape seed oil, cottonseed oil and the like) and similar products in bulk order shipped for a low price. So, suddenly became popular food, heat in these oils. It has also become a popular margarine containing a large amount of TRANS-oil and linoleic acid. As a result of advertising, announcing that margarine lowers cholesterol and, thus, is beneficial to health, the consumption of margarine for some time has increased dramatically. Actually, the most commercialized products vegetable oils are produced using the process of extraction solvent (e.g. n-hexane). In the most commercialized products vegetable oils are pure neutral fats in a very light and transparent, without polar fats, containing large amounts of unsaturated fatty acids. From the points of view of the evolutionary process of man, you can easily conclude that nowadays people consume too many neutral vegetable fats containing large amounts of unsaturated fatty acids. In other words, I believe that is physiologically a revolutionary change, which can strongly influence the fat metabolism in humans. In the long course of evolution man ate a fatty acid containing fatty acid CIS-type in its natural state, but currently consumes a large amount of fatty acids TRANS-type. As a result of evolution the human body has no enzyme capable of converting fatty acid TRANS-type fatty acid CIS-type. The dietary fatty acids TRANS-type slows down fat metabolism. Thanks to the development of public transport and various facilities, the level of physical activity is declining rapidly, and, thus, a state is unable to convert ingested fatty acids into energy in the human body. In addition, we can assume that the temperature of the support received by the human body, has increased dramatically due to the development of heating systems and materials for making clothes.

In conclusion, we can say that there were created conditions favorable for the occurrence of skin diseases such as atopic diseases, and JI is the IAP, because of the new imbalance of lipid metabolism due to decreased conversion of fat into energy, excessive consumption of neutral fats containing unsaturated fatty acids, consumption of TRANS oils and reduce the level of physical activity, and also appeared environment, which can cause enlargement of the capillaries and abnormal function of the capillaries due to the temperature increase, in which there is human activity.

Differences and similarities between psoriasis and atopic disease

About lung damage due to eating a large number of unsaturated vegetable fatty acids can learn from the study of Wolfe et al. (Wolfe R.R., Martini W.Z., Irtun o, H.K. Hawkins, Barrow R.E. (2002). Dietary fat composition alters pulmonary function in pigs. Nutrition. 18:647-653). The elasticity of the lung tissue is lost, and proteins in blood plasma excudit when the intake of vegetable oils, reducing, thus, functions. Similarly, on the skin may affect the consumption of large amounts of unsaturated fatty acids. Patients suffering from atopic disease have higher levels of HDL cholesterol (Schafer, T., et al., (2003). Intake of unsaturated fatty acids and HDL cholesterol levels are associated with manifestations of atopy in adults. Clin. Exp. Allergy. 33:1360-1367). This can be interpreted in such a way that after dietary fat, active fats are delivered to all organs. Shipping is IRow, contains unsaturated fatty acids in the skin can affect the membrane components of the epidermal cells and cells of blood vessels, and unsaturated fatty acids having a high fluidity, can decrease the function of blood vessels, causing, therefore, exudation of blood plasma proteins, especially albumin and immunoglobulin G (IgG). This exudation is carried out through the gaps between the cells of the blood vessels, and therefore the size seeping proteins is limited. IgG having the size of 150 kDa, emerges with ease, but proteins having dimensions greater than that of IgG, as described above, appear to work. The specified mechanism exudation can be observed in a patient suffering from psoriasis, as well as in a patient suffering from atopic disease. From this we can conclude that erythroderma or swelling, available for psoriasis and atopic disease may appear as a result of changes in the function or structure of the blood vessels, except in the case of infection or severe physical irritation. It is important that psoriasis and atopic diseases are very different from each other metabolic. Although patients suffering from atopic diseases have a high level of HDL cholesterol, patients suffering from psoriasis have a very high cholesterol levels and triacylglyceride in the blood. Titbits is, the size of the sebaceous glands, secreting sebum from the neutral fat components, in patients suffering from psoriasis are too small. According to a simple analysis, it is shown that may be a problem with the supply of fats that are required for the synthesis of sebum from the blood vessel. Similar case for atopic diseases is that the content carmignola lipid that is required to protect the skin, the epidermis is low. Although the profiles of fat that are found in the blood of psoriasis and atopic disease, differ from each other, active fat metabolism in the body between them is common. The General position, which is especially worthy of mention for psoriasis and atopic disease is the exudation of blood proteins in both diseases. We can conclude that although the metabolism of fats actively occurs in the body may have a problem with the delivery process of fats in the epidermis, or special fats that are needed are not delivered to the epidermis.

A new understanding of the inflammatory response and protein exudation of blood

Common to psoriasis and atopic diseases is that the proteins of blood seeping from microvascular and then seep into the skin tissue. Sweaty proteins have limited the molecular the second mass, and they contain a large percentage of immunoglobulin G (IgG, 150 kDa) and serum albumin (66 kDa). It can be expected that proteins, sweaty skin, can slowly dry out, randomly contact (accidental binding with low affinity), the non-contact, selectivity to contact or aggregate with each other, at the same time enhancing environmental salt concentration, in contrast to the proteins within blood vessels. You can track continuing education vicious circle, which is that sweaty amount of protein increases during stimulation of the secretion of histamine due to physical stimulation by scratching and burning sensations of the skin as it dries proteins. We can conclude that while there are no allergens or infection of the external origin, the phenomenon of non-specific or random aggregation sweaty antibodies can be recognized as the same signal in case of an infection; first in the tissue move neutrophils, and, thus, may occur recruitment of various immune cells. Particularly it is shown that the phenomenon of recruitment of macrophages into the tissue in cases of chronic atopic diseases is generated immunological mechanism of Th2 cells due to continuous antigenic exposure. You can, however, illustrate that this phenomenon is simply generated by the mechanism of purification of aggregation sweaty plasma proteins. An example of this mechanism of purification includes the destruction of agglomerated clusters of the surfactant proteins and fats macrophages in idiopathic alveolar deproteinize. It is possible to explain the movement and activation of eosinophils observed in atopic disease, from the point of view of symptom exudation of proteins. It is well known that eosinophil secretes a cationic proteins. This can be a simple cytological mechanism to remove sweaty proteins after agglomeration sweaty proteins. In addition, it is easy to understand that eosinophils can be recruited in the area of exudation in order to reduce exudation of blood proteins that continuously occurs in atopic disease, like the recruitment of eosinophils to control or reduce the exudation of blood proteins after recruitment of eosinophils due to infection or allergen sensitization in the pleural cavity.

A new way of dealing with psoriasis and atopic diseases

On the above basis, if the psoriasis and atopic diseases are usually caused by imbalance and impaired lipid metabolism, and, as a result, induced by various inflammatory response by infiltration and then agglomeration proteins of blood leaking from blood vessels into the tissue, you can offer a new way of treatment, the Oia above diseases.

As a method of treatment of diseases, which are the most important and superior importance, you should reduce the intake of foods with vegetable oils, especially vegetable neutral oils, and food should be prepared without using a method of production of TRANS-oils in the cooking process, or you should not eat foods containing TRANS-oil. Because this method of power control should be implemented until such time as the lipid components in the body will not change until a certain level, the method requires a considerable amount of time and effort. There are problems that lie in the fact that as patients with atopic diseases are suffering from severe itching, the treatment period is long lasting, but the method of controlling the power supply should be used.

The second method is a method of alleviating inflammation and then restore the epidermis to a normal state by suppressing local exudation of blood proteins in the affected area. The authors have previously proposed such a method, which is currently registered as a patent in Australia, Singapore and Russia, in addition to Korea (Korea patent 0891595, patent Australia 2006217261, patent PCT application number PCT/KR2006/000638). How is that fat metabolism in the relevant cells and vascular cell is changed, and exudation of blood proteins is suppressed by applying the composition containing genesisone phospholipids that are present in large quantities in the affected area. This method requires the treatment period, i.e. an average of 8 to 12 weeks, and in the case of a patient with severe symptoms, it requires a longer period of time.

The third method is a method proposed in the mentioned patent, to remove sweaty proteins released into the affected area using bandages for absorption of proteins. With this method you can expect most of the short treatment period, i.e. an average of 10 days, and it is a very stable way, because it is not the method of delivery of any materials or effective components in the skin and quickly relieves pain caused by itching. However, there is a possibility of re-occurrence of the symptom, because proteins can again be a good exercise, if the method is used without reducing or suppressing the exudation of blood proteins. Ensure no recurrence and complete cure can be expected within a short period of time with simultaneous application of a bandage to remove exudation of blood proteins, indicated in this patent, in combination with treatment, the overwhelming exudation of proteins in different ways.

Description of the invention

the technical problem

The present invention was developed to solve the above problems and needs, and the present invention is the creation of a bandage for the treatment and relief of symptoms of skin diseases, in which there is exudation of blood proteins.

To achieve the above objectives, the variant example of implementation of the present invention relates to a bandage for the treatment of skin diseases or alleviate symptoms of skin diseases, in which there is exudation of blood proteins, and this bandage comprises a) a polymer matrix with microsaccades structure and (b) polar resin to bind to the proteins included in the matrix, and/or resin, hydrophobic-related proteins included in the matrix.

According to a variant implementation of the present invention, the polymer matrix with microsaccades structure may preferably be microsaccade the structure of complex carbohydrate selected from the group consisting of agar and agarose, and microsaccade structure using polyacrylamide, latex, polystyrene, polyvinyl chloride, silicone, polyurethane or cellulose fibers, but the present invention is not limited to them.

According to a variant implementation of the present invention, the polar resin comprises an organic or inorganic matrix containing functional the th group, which is ionic or capable to ionize in appropriate conditions of pH. The organic matrix may be a synthetic material (for example, acrylic acid, methacrylic acid, styrelseledamot, divinilbenzola) or partially synthetic material (for example, modified cellulose and dextran). Preferably, the inorganic matrix includes silica gel, modified by the addition of ionic groups. Covalently bound ionic group may be a strong acid (e.g. sulfuric acid and phosphoric acid), a weak acid (e.g. carboxylic acid), a strong base (e.g., primary amine), weak base (for example, Quaternary amine) or a combination of acidic groups and basic groups. Typically, the ion exchanger, which is suitable for use with ion exchange chromatography, as well as for deionization of water is also suitable for controlled release of drugs. These resins are described in “Principles of Ion Exchange” (pp. 312-343) and in “Techniques and Applications of Ion-Exchange Chromatography” (pp. 344-361), Chromatography (E. Heftmann, compilation), van Nostrand Reinhold Company, New York (1975), H.F. Walton.

Examples of the polar resin in the present invention preferably include agarose, Sephadex, or separate with a group of DEAE (diethylaminoethyl); agarose, Sephadex, or separate with the group CM (carboxymethy the l); the agarose, Sephadex, or separate with trimethylammonio group; a resin having sulfonylurea derivative or derivatives of sulfonic acid as a functional group; polar resin from granules of hydroxyapatite or polystyrene patterns. However, the present invention is not limited to them.

According to a variant implementation of the present invention, the resin-related proteins through hydrophobic interactions, preferably, includes a hydrocarbon chain of 4 to 10 carbon atoms, but the present invention is not limited to them.

According to a variant implementation of the present invention, a variety of resins having different polarity, preferably, placed in a particular order in the bandage. As for the multilayer bandages, more preferably, a polar resin having a positive charge, the first contact with the affected area, and a polar resin having a negative charge, was located on the rear side. However, the present invention is not limited to this.

According to a variant implementation of the present invention, the specified skin disease includes atopic dermatitis, eczema, psoriasis, contact dermatitis, erythema, herpes, chronic or contact urticaria, nodular the prurigo of Hyde (prurigo nodularis) and a slight burn or scald, or the arene, which does not damage the outer layer of the skin. However, the present invention is not limited to them.

According to a variant implementation of the present invention, more preferably, the bandage of the present invention is additionally included genesisone phospholipids, organic acids and divalent cations. Genesisone phospholipids are densisty a phospholipid derived from the lung of an animal, and their specific examples include DPPC, DPPI, etc. a Specific example of the organic acids include organic acid that is involved in the Krebs cycle, such as citric acid, and a specific example of the divalent cations include ions of calcium and magnesium.

In addition, the present invention relates to the outer bandage, comprising a) a polymer matrix having microsaccade structure, and (b) polar resin included in the matrix, in which the outer dressing can absorb blood proteins, which have promotely on the skin.

In addition, the present invention relates to a bandage for the treatment of skin diseases or alleviate symptoms of skin diseases, in which there is exudation of blood proteins, and this armband is made directly fixing a functional group that is associated with proteins, to the matter, the swab or gauze.

According to a variant implementation of this is bretania, functional group, which can be directly fixed to the matter, the swab or gauze may preferably be a DEAE-, CM-, trimethylammonium group or sulfonic acid, or a functional group having a hydrocarbon chain length from C4 to C10. However, the present invention is not limited to them.

In addition, the present invention relates to the outer bandage, made directly fixing a functional group that is associated with proteins, to the matter, the swab or gauze, and the outer bandage can absorb blood proteins, which have promotely on the skin.

In addition, the present invention relates to a bandage for removal of proteinaceous wastes, which are secreted on the skin, the bandage comprises a) a polymer matrix having microsaccade structure, and (b) polar resin to bind to the protein included in the matrix, and/or resin to bind to the protein through hydrophobic interactions.

In addition, the present invention relates to a bandage for the diagnosis of skin diseases, which is the exudation of blood proteins, and the bandage comprises a) a polymer matrix having microsaccade structure, and (b) polar resin to bind to the protein included in the matrix, and/or resin to bind to the protein through hydrophobic interactions.

As shown in experimental example 5, and 6 of the present invention, there is a distinct difference between protein profile in patients suffering from psoriasis, and protein profile in a patient suffering from atopic disease. Ig or protein albumin are examples of protein profiles. The difference between the two diseases can be clearly identified using protein profiles described above. It is possible to find the marker proteins of various skin diseases by the method of absorption or diagnose various skin diseases through standardization of the pattern (pattern) exudation of proteins.

Hereinafter the present invention will be described in more detail.

The present invention relates to a bandage for absorption and then remove sweaty proteins in the blood that has penetrated the skin tissue, by directly apply it on the affected surface with skin diseases (such as atopic dermatitis, eczema, psoriasis, contact dermatitis, and the like), in which the exudation of blood proteins. Dressing removes proteins, sweaty from epidermal tissue to reduce inflammation of the skin and, at the same time, allowing water to remain in the skin, so that skin disease quickly and safely treated or alleviated. The bandage has a matrix that can turn on the water by using the Oia polymer, having microsaccade structure that can sufficiently pass through extravascular sweaty proteins and peptides, for example, foaming sponge of agar (or agarose), polyacrylamide, latex or polyurethane. The bandage should remove proteins and peptides into the skin, by fixing the various charged resin (diethylaminoethyl)cellulose and CM (carboxymethyl)cellulose, commonly used for chromatography of proteins, carbohydrate complex (derivationally complex carbohydrate compounds) with other charged groups, charged resins from granules of hydroxyapatite and polystyrene structure, and the like) with a large surface area due to small particles in the structure of the matrix, and then binding proteins and peptides into the skin. The present invention is based on the hypothesis that, from the point of view of skin diseases such as atopic dermatitis and psoriasis, blood proteins propotevaet of the blood vessel due to disorders of fat metabolism and imbalance intake of fat from food, and then there are various inflammatory reactions, skin damage and hyperplasia of epidermal cells due to exudation described above. The present invention provides a method for rapid and safe treatment of atopic dermatitis, eczema, psoriasis and diseases with similar symptoms, offers by the taxpayer therapeutic opportunities for treatment of very severe atopic disease in the next 10 days through the use of bandages, which can absorb and then remove sweaty from the blood proteins and peptides penetrated into the skin tissue through absorption sweaty from the blood proteins and peptides fixed with resin. In addition, the present invention enables a new understanding of the diseases described above, and provides various applications developed using an armband.

I think that similar diseases, such as atopic dermatitis, eczema and psoriasis can be caused by a violation of fat metabolism and imbalance of the metabolism of fats in the blood proteins propotevaet, and can cause a variety of inflammatory reactions or hyperplasia of epidermal cells due to blood proteins, penetrated into the fabric. The present invention relates to a method very quick and effective treatment of skin diseases through the bandage on the affected area, fixing various resins, for example, DEAE-cellulose or agarose), resins having the CM group and hydroxyl Apatite, resin Dowex etc. in agar gel, or applying wet dressings after binding of a charged group that can bind with proteins, on a clean cotton cloth.

Effect

As confirmed by the present invention, suppose that the bandage and absorbent proteins cloth for wet dressings on the present and the gain are the most secure method of treatment, because the epidermis is not made any other medicines or specific components, in addition to distilled water, for the treatment of atopic disease. It is expected that the method of treatment that can treat severe atopic disease within 10 days in accordance with the present invention, can provide a variety of new treatment methods and new understanding of the causes of atopic diseases.

Figure 1 presents a diagram illustrating the structure of the bandage of the present invention. It is made in such a way that the outer part of the bandage is in close contact with the affected area for absorption of blood proteins, sweaty from the blood vessels. 1 - Bandage, which is a fixing film, such as Tegadermm TM production 3M Co. Ltd., or polyvinyl chloride with a porous structure for the supply of oxygen to the skin, and has a material that is capable of properly to keep water and flowing oxygen. 2 - matrix with microsaccades structure that can hold water, such as agar. 3 is a Resin having a strong polarity, carbohydrate complex (derivationally complex carbohydrate)having a polar group, such as DEAE-cellulose, or a polar resin, such as hydroxylapatite. 4 - Cotton gauze or polyester fiber, attached to the gel to prevent Legkov the breaking of agar gel component in the crease or on the curved surface of the body. 5 - Adhesive tape.

Figure 2 presents a diagram illustrating an example of the structure of the bandage of the present invention. If the resins have various functional groups or have different polarity, for example, DEAE-agarose and CM-agarose are used together, when the resin is mixed in the same gel resins are linked to each other so that there is a high probability of reducing the efficiency of absorption of proteins. If the polarities are different, as described above, it is preferable that the epidermis was applied two gel twice. In particular, small proteins with a positive charge, effectively absorbed, because due to the fact that most proteins are negatively charged, a polar resin, such as DEAE with a positive charge, the first is in contact with the affected area, and resin, such as CM, is placed on the back because of the relatively active movement of molecules and rapid distribution, since proteins with a positive charge, usually have low molecular weight (e.g., eosinophilic cationic protein, 18-232 kDa). 6 is a Resin having a different polarity.

Figure 3 presents a diagram illustrating the functional mechanism of the bandage of the present invention. It mimics the mechanism, which is that after dressing the tree of blood, penetrated into the tissue of the epidermis after transudation from the blood vessels, diffuse in the dressing and then contacted with a bandage. The inflammatory reaction is facilitated by the absorption of sweaty proteins of blood in the dressing through contact absorbing protein bands with the epidermis and remove, thus, sweaty proteins in the blood, as well as the affected area, damaged atopic disease or psoriasis, can recover quickly by storing water in the epidermis and adding water.

Figure 4 and 5 shows a diagram illustrating an example of application of the bandage of the present invention in atopic eczema. Figure 4 shows a photograph illustrating the dressing in atopic eczema, in which the bandage is applied on the upper part of the foot 36-year-old man suffering from severe atopic eczema. Used a 2.5% (wt./about.) agar gel (2 mm thick)containing 10% (wt./about.) DEAE-cellulose. The residence time of the bandage on the skin ranged from 20-21 hours to 8 a.m. every day. There was a significant improvement in symptoms after one day of use bandages, and then, starting with three days of use, the symptom has improved to a certain extent, in which the boundaries of the affected area was difficult to determine. Figure 5 presents a photograph of illustrer the maintenance analysis SDS-PAGE of proteins, soak in the dressing of the present invention, for which the band used by patients suffering from atopic eczema, cut into pieces of a certain size, was dissolved in sample buffer for SDS-PAGE and then placed in the apparatus for electrophoresis. Used 10% (wt./about.) polyacrylamide gel, and proteins showed staining of STS-R250. It was found that among the absorbed proteins the main protein was serum albumin (66 kDa) and immunoglobulin (heavy chain 52 kDa and a light chain 27 kDa). Proteins on the 7th line was a profile of all whey proteins. The biggest difference with sweaty proteins obtained from the affected area, was the presence of proteins with a mass of 200 kDa or more. As the number of sweaty protein (or a number that can represent a number of sweaty protein associated with a bandage), penetrated into the skin tissue, decreased sharply, the condition of the affected area quickly improved. It was confirmed that the phenomenon of exudation of proteins closely associated with the severity of atopic diseases.

Figure 6-9 illustrates an example of the bandage of the present invention to a specific patient in children suffering from severe atopic dermatitis.

Figure 6 illustrates an example of the bandage with severe atopic d is ratite (in the knee), when the bandage containing a 2.5% (wt./about.) agar gel (thickness ~2 mm), which contained particles of 10% (wt./about.) DEAE-cellulose was placed 7-year-old boy suffering from a symptom of severe atopic dermatitis. A bandage was applied to the patient for the night. Skin condition with severe lesions was significantly improved day by day. Itching lasted until 4 days after dressing, but 8 days found no symptom of itching, and the epidermis is largely normalized.

Figure 7 shows a photograph illustrating the analysis sweaty proteins associated with dressing in the knee region of the patient in children suffering from severe atopic dermatitis. Headbands, taken from the affected area daily at the same time cut into pieces of a certain size and then subjected to the analysis of SDS-PAGE to visualize the proteins, which were diffundiruet of the epidermis and then contacted with a polar resin. It was found that the major proteins were albumin and immunoglobulin serum. In the result, it was confirmed that the number of sweaty proteins closely associated with the restoration of the affected area.

On Fig illustrated by the example of the bandage to a patient in children suffering from severe atopic dermatitis (in the calf). The results observed poolenalena bandage on the area caviar 7-year-old boy, suffering from atopic dermatitis. The dressing consisted of 2.5% agar gel containing 10% (wt./about.) DEAE-cellulose, which was manufactured in such a way that contained 10 mg/ml phospholipid extracted from pig lung, 1.5 mm CaCl2and 5 mm citrate/citric acid (pH 5,8) in water gel. The specified component is a "composition, inhibiting exudation of blood proteins"as used in the patent (patent Korea 089195, patent Australia 2006217261, PCT application number PCT/KR2006/000638). It was easily confirmed that the bandage containing a phospholipid, as described above, shows a more stable therapeutic effect (6) compared with a bandage, which contains only water.

Figure 9 presents the analysis sweaty proteins, soaked bandage applied to the area of the calf of the patient's childhood, suffering from severe atopic dermatitis. It was confirmed that the bandage containing a phospholipid, can continuously absorb leaking proteins over an extended period of time. I believe that there is a high probability that the phospholipids act as a mild detergent, so that the agglomerated sweaty proteins uniformly diffuse. In addition, there was also the likelihood that citric acid disrupts the binding of engineered proteins, contributing to the destruction of p is apoteosi proteins. According to the results of SDS-PAGE it was found that although the bandages were presented many lipids, they do not prevent the absorption of sweaty proteins into the skin. Thus, I believe that since the wet wraps used for an extended period of time, can affect the skin barrier, although he applied the bandage containing lipid component that can protect the skin barrier, it is possible to obtain a stable therapeutic effect of a bandage. Especially, in order to achieve a more stable treatment, I believe that it is possible to use a method of mixing of the composition overwhelming exudation of blood proteins containing phospholipids extracted from pig lung, as the main component, with gel bandages and then apply.

Figure 10 and 11 illustrate examples of the application of a bandage according to the present invention on the face in case of severe atopic dermatitis. In Fig. 10 shows the effect of the bandage after its imposition students female with severe atopic dermatitis on both sides of the face. After dressing from day to day easily experienced a more rapid recovery. By the 4th day after applying bandages symptom improved, so that the boundary of the affected area was not determined, and 8-th day has recovered normal skin condition.

Figure 11 is barbaraanne proteins, collected from gel bands, superimposed on the face, were subjected to SDS-PAGE. It was found that lowering the number of sweaty proteins corresponds to the degree of recovery of the epidermis.

On Fig and 13 illustrate examples of the application of double headbands with different polar resin; the bandage was made by placing a 2.5% (wt./about.) agar gel (~2 mm)containing 10% (wt./about.) CM-cellulose, 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) DEAE-cellulose (see figure 2). A bandage was applied to the affected area 45-year-old man who suffered from atopic eczema, and then observed the effect and extent of absorption of proteins headbands using SDS-PAGE.

On Fig illustrates the condition of the skin after applying double headbands with different polarity.

On Fig illustrated proteins subjected to SDS-PAGE, which were extracted from the gel dressings after applying on the affected area.

On Fig-18 illustrates examples of the bandage containing different pitches on each of the affected areas in a patient with psoriasis.

Headbands were made in such a way that they contain resins with different polarities, and then put them on the psoriasis area 28-year-old woman. Bandages were applied for 6 hours, and each effect bandages were observed on the basis of the degree of the Yeni reduction of epidermal thickness and color of epidermis. (Fig) gel (thickness ~2 mm)formed by use of only 2.5% (wt./about.) agar (Fig) to 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) DEAE-cellulose (Fig) to 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) CM-cellulose, and (Fig) to 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) hydroxyapatite (bipolar resin), was applied to a patient with psoriasis, respectively. Bandage containing DEAE-cellulose showed the best effect, and dressing containing CM-cellulose showed no clear effect.

On Fig illustrated the protein pattern obtained from the affected area of the patient, who suffered from atomic dermatitis, and protein obtained from the affected area of a patient suffering from psoriasis. The result provides the basis under which these two diseases are caused by exudation of proteins in equal measure, but the types sweaty proteins differ.

On Fig illustrates the results of observation after dressing, consisting of a 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) DEAE-cellulose, damage caused by external physical impact, as an example of damage (negative effect). It was assumed that even proteins required for healing of the lesion, is absorbed into the dressing and bandage soon reduces the efficiency of the treatment of damage. Absorbed by blood and yellow proteins was observed at the bandage is removed after applying for 6 hours. After you remove the bandage was observed that if the epidermis is repeatedly pressed, the affected area is poorly bled. In addition, it was observed that even if the damage was closed, he left a large scar. The bandage of the present invention is not limited cutaneous disease, which occurs when the exudation of blood proteins, such as atopic dermatitis or psoriasis without external damage.

On Fig presents a scheme illustrating the process of manufacturing DEAE-cotton fabrics. The method of binding DEAE-groups to cellulose was optimized to use cotton fabric with attached DEAE-group for the treatment of atopic skin disease or psoriasis, as well as the method of manufacture has been simplified for mass production. On Fig presents a diagram illustrating the process by using method, prepared in the laboratory. DEAE-group was added with continuous movement of tissues with different thickness and cell size. I believe that this method can be used in various ways, in accordance with skin symptoms.

On Fig and 22 photographs illustrating the absorption sweaty proteins using DEAE-cotton is anagnou tissue. DEAE-cotton fabric made by joining DEAE-groups to the basic cotton fabric. Left side on Fig was a sample drying, and the right side was a model of wetting with distilled water before applying to the affected area. Absorption sweaty proteins was confirmed by applying the cloth to the affected area with atopic eczema. It was easily confirmed that a small number of proteins were detected on the main cotton fabric, but revealed a large number of different sweaty proteins in the blood (Fig). The specified fabric, capable of binding a protein or a polar group can be applied on the affected area having a sharp bend. In addition, it can be expected that in case of defeat dermatitis entire body, it can be manufactured in the form of service, so that you can effectively treat the whole body. In addition, it is expected that as in the case of fabric, you can mix different drugs and then to use them, medical professionals can make specially adapted treatment by adding liquid medicines in accordance with the patient's condition.

Best mode for carrying out the present invention

Hereinafter the present invention will be described in more detail with reference to the not limiting the following examples. However, the following examples are intended only to illustrate the present invention, and the scope of the present invention is not limited to the following examples.

Example 1: Manufacture of headbands for removal of the exudate proteins in the blood

Agar (or agarose) is an experimental material that is commonly used in molecular biology, not biodegradable available in vivo by enzymes, is edible and can produce a type of very good gel, which does not irritate the skin. The specified type of gel has excellent flexibility, can have a large amount of water, and has many advantages. In addition, particles with a higher molecular weight can diffuse between the microwells formed in the gel, and can easily be removed. Usually when using agar electrophoresis diffusion of proteins with a molecular mass of 200 kDa or less in the gel is too fast, so that it is difficult to confirm the protein bands. This means that micromata structure of the agar is too large. Because there are a lot of immunoglobulin (IgG, 150 kDa) and serum albumin (66 kDa) molecular mass of 200 kDa or less as blood proteins propotevaet in the epidermis, there is no problem concerning the free diffusion of proteins in the gel.

The polar resin h is example, resin, such as DEAE-cellulose or DEAE-agarose, CM-cellulose or agarose) and hydroxylapatite)that are associated with proteins in the gel and fix the proteins in the gel can irritate the lung and mucous membrane in the powdered state, but in the case of complete hydration or swelling irritation is missing. According to the present invention, unnecessary irritation can be minimized by distributing the particles in the gel, such as agar, fixation and direct contact with the affected area.

Resin, which should be fixed in the gel, such as agar, was immersed in distilled water at night for a sufficient swelling. Each of the resins were washed in 0.1m NaOH - 0,1M HCl - 0,1M NaOH or 0,1M HCl - 0,1M NaOH - 0,1M HCl to remove contaminants attached to a polar group. Resin without contaminant again washed several times with distilled water, and then washed resin autoclaved under the high temperature and high pressure (15 minutes, 15 lb/cm2).

The process of mixing the agar gel (or gel agarose) with resin and then fix was as follows: after heating agar gel (2.5% ratio weight/volume) to cook in the liquid phase, the temperature was maintained at 60°C. the Prepared resin was produced in the form of sediment on the filter, the water from the resin was removed, and then the mass of the Ola picked up so so it was 10% (ratio of weight/volume) of the dressing. Agar gel and homogeneous resin was mixed at 60°C, was poured into the mold and then cooled, to obtain a gel with a thickness of 1.5 mm to 2 mm, Because when the gel, such as agar, were applied to the curved part of the body, too folded or bent, the gel can be destroyed, a single layer of cotton gauze (mesh 80 to 120) were applied to the surface of the gel to compensate for the strength of the gel state of the liquid gel. The structure and principle of action of the gel is illustrated in the diagram (Fig.1-3).

Experimental example 1: an Example applied to the affected area with atopic eczema

Bandage, manufactured by fixation with 10% (wt./about.) DEAE-cellulose to 2.5% (wt./about.) agar gel applied to the affected area of the patient (male 36 years old)with very severe atopic eczema. The patient suffered from atopic eczema for a long period of time, i.e. for 10 years or more, because the affected area on the upper part of the foot. The bandage is not applied in the daytime, when there is a variety of activity, and inflicted about 20-21 hours at night and removed about 8 o'clock in the morning. The affected area was observed every day. The gel samples were collected from the bandages removed from the affected area, in a certain amount using a cylinder with a diameter of 2 is m, and the dissolved proteins were subjected to 10% (wt./about.) SDS-PAGE electrophoresis using sodium dodecyl sulfate-polyacrylamide gel). After electrophoresis, protein bands were stained with Kumasi brilliant blue - R250.

The analysis of proteins associated with a bandage, remote from the affected area, it was found that the largest number of proteins were serum albumin, and the second largest amount of protein was protein immune antibody (heavy chain ~52 kDa light chain 27 kDa). The result corresponded to the fact that the exudation of blood proteins was carried out in accordance with the molecular weight. It was found that when the amount of protein that has soaked into the blindfold (i.e. the number of sweaty protein in the blood), decreased, the condition of the affected area was dramatically improved. This result is an indirect result of the verification of the fact that the exudation of tissue proteins in the blood contributes to atopic dermatitis. He shows a surprising fact, which is that atopic skin disease can be treated without any drugs having efficacy, such as steroids of any kind, derived from steroids, medicines, exercising immune control (for example, Elidel or Tacrolimus), and moisturizing ointments. With the persons of the present invention is a very stable way, because the treatment time is very short, and there are no components that should be absorbed into the skin, in addition to distilled water (figure 4 and 5).

Experimental example 2: Example application in severe atopic dermatitis in a typical child (the experiment was carried out at the content in the bandage of specific phospholipids)

A bandage was applied to partially affected area 7-year-old boy with severe atopic dermatitis on the body. Put a bandage of two types.

a 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) DEAE-cellulose, and 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) DEAE-cellulose, 10% (wt./about.) phospholipids extracted from pig lung, 1.5 mm CaCl2and 5 mm citrate/citric acid (pH 5,8) impose on the various affected regions, respectively, and compared the effects. Component of phospholipids extracted from pig lung, 1.5 mm CaCl2and 5 mm citrate/citric acid (pH 5,8) is a composition for suppressing the exudation of blood proteins for the treatment of atopic dermatitis (Korea patent 0891595, patent Australia 2006217261, patent PCT application number PCT/KR2006/000638), and currently completed clinical trials phase III for admission as a new drug. The rate of treatment was observed when ispolzovaniem applying bandages two species in the affected area, and watched the profile sweaty proteins. In addition, it was studied how the added phospholipids were interrupted by the diffusion of the protein in a bandage.

The use of bandages two species, it was found that both types of dressings showed a very significant rate of treatment and the effectiveness of the child with typical severe atopic dermatitis. It was found that the bandage containing phospholipids, calcium ion, citrate/salt of citric acid, absorbed sweaty proteins more efficiently. As for the effect of treatment, it was found that the bandage containing phospholipids extracted from pig lung, more stable treated skin and then normalize the skin. It was assumed that the phospholipids extracted from pig lung, act as a mild detergent for dissociation agglomerated proteins that propotevaet and then stimulate the skin, so they demonstrate a good effect on the removal of the exudate. In addition, there is the likelihood that the citric acid contained in the composition, interrupts the binding of ions which may occur between proteins, so that the exudate can be more effectively removed. I believe that because saturated phospholipids contained in the dressing, have the effect of suppressing the exudation of blood proteins, f is spolied provide a more rapid recovery of the affected area. By comparing the effects of two types of dressings (bandages, containing only DEAE-cellulose, and dressings containing DEAE-cellulose and phospholipids extracted from pig lung, + 1.5 mm CaCl2+5 mm citrate/citric acid (pH 5,8)) was confirmed as an important fact that phospholipids do not interrupt link sweaty proteins with particles of a polar resin, fixed in the bandage.

With the aim of obtaining a fast and stable treatment effect, it is assumed that the medicinal product or the components having the function of suppressing the exudation of blood proteins, it is preferable to use together.

The wet wraps used for the treatment of atopic dermatitis. With the aim of continuous application of dressings containing large amounts of water, according to the present invention assumes a method of dressing that contains a variety of lipids and components, capable of compensating the skin barrier can be a good way of alleviating pain in a patient suffering from atopic dermatitis. In addition, it is assumed that since we know that ointment, such as a steroid ointment or Tacrolimus, have the effect of suppressing the exudation of blood proteins, in addition to their original anti-stress activity and functions of reducing immune responses, can be expected to increase the treatment effect is when you use headbands, made by mixing proper amounts of drugs capable of suppressing the exudation of blood proteins in the matrix dressings, or use bandages while suppressing the exudation of blood proteins by the use of drugs capable of suppressing the exudation of blood proteins before and after dressing.

Experimental example 3: Example of overlay on the face of a teenager suffering from severe atopic dermatitis

The result was observed after dressing on both cheeks teenager (16-year-old girl), who suffered from severe atopic dermatitis. The patient suffered severe atopic dermatitis, which did not allow her to lead a normal life due to severe itching and burning sensations. The effect of the dressings had to be studied on the face as neutral fats are secreted in large quantities in the form of sebum, inhibiting thus, the effect of the bandage against the absorption of protein. As headbands used a 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) DEAE-cellulose. A bandage was applied during an afternoon NAP and then removed in the morning before school. After you use headbands symptom was improved every day, and by the 8th day of use bandages facial skin is restored to a normal state. The skin condition of the patient remained settled for approximately 20 days, and then both cheeks flushed again, and there was a slight symptom of atopic disease.

According to the results of SDS-PAGE confirmed that removing sweaty proteins using headbands requires an average of 5 days, and in the case of a patient with severe disease require treatment period of 8 to 10 days. Mainly, it is assumed that the amount of protein or antibody-based test decreased, and then improved symptom. In conclusion, it is assumed that the number of sweaty blood proteins directly associated with the presence of mild or severe symptoms, and atopic disease can be easily treated as long, while at the same time is a diverse and active treatment, are able to suppress the exudation of blood proteins.

Experimental example 4: Example of overlay double headbands gel type containing resins with different polarities

Double the dressing was made to have different polarities, the application of a 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) CM-cellulose, 2.5% (wt./about.) agar gel (thickness ~2 mm)containing 10% (wt./about.) DEAE-cellulose (see figure 2). A bandage was applied on the affected area, the 45-year-old man who suffered from atopic eczema, and then observed the effect and absorption of proteins in a bandage. On the first day the bandage was applied on the affected areas shall be 3 and a half hours and then imposed at the time of sleep every day. After 3 and a half hours after dressing condition has improved significantly and dramatically improved every day.

It is assumed that the number and type of sweaty proteins, dissolved gel was more diverse, friendly, compared with only DEAE-cellulose. There was also a much more rapid effect of treatment.

Experimental example 5: application Example in a patient with psoriasis

The effectiveness of the dressings was observed after applying bandages with different combinations on the skin 28-year-old woman, who had psoriasis, spread throughout the body (mainly the symptoms were heavier in the area, legs and arms).

These gels are applied to a patient with psoriasis, respectively, approximately 5 hours and then removed. From this point, the affected areas were observed. The best effect was observed in a patient with psoriasis when using bandages from a 2.5% agar gel containing 10% (wt./about.) DEAE-cellulose, and the dressing had the bad effect, was a bandage from a 2.5% (wt./about.) agar gel containing 10% (wt./about.) CM-cellulose (see Fig-17).

A. The gel formed by only 2.5% (wt./about.) agar (thickness ~2 mm);

b. a 2.5% agar gel containing 10% (wt./about.) DEAE-cellulose;

C. a 2.5% agar gel containing 10% (wt./about.) CM-cellulose;

d 2,5% agar gel, containing 10% (wt./about.) hydroxyapatite (bipolar resin).

The most interesting discovery was that the types of proteins, propoaala from the affected areas in a patient with psoriasis and patients with atopic disease were different. In the case of a patient suffering from psoriasis, revealed albumin, but the immunoglobulin found in very small quantities. I believe that when proteins propotevaet of the blood vessel, is selective exudation in accordance with the molecular weight. It can be expected that proteins or antibody-based test with a higher molecular weight than albumin, not propotevaet with such ease. In the result, it is assumed that the reason why the inflammatory reaction is more active in the case of atopic dermatitis can be described and the reason is rather pathological mitosis epidermal cells than inflammatory reaction in the case of psoriasis or skin damage. According to the observations described above, it is possible easy visual diagnosis of psoriasis and atopic diseases with the use of a bandage of the present invention. In other words, when the difference between atopic dermatitis and psoriasis is questionable, the bandage of the present invention can be used as a diagnostic criterion. Besides, when is ispolzovanie immunological research method, it becomes possible studies of different proteins. Now the bandage of the present invention can be used for various applications, for example for the purpose of research, in addition to treatment goals.

Experimental example 6: Example of dressing for external damage or injury (an example of a negative effect bandages)

A bandage applied to a cut or wound and then watched its effect. The result assumes that the imposition of absorbing proteins bandage on the wound is not preferred. This is because the absorbed even proteins required for blood clotting and tissue repair, and after applying for 8 hours again called light bleeding. In addition, the rate of wound healing was significantly slowed down, and it was easy to be infected, because the wound was left open. In addition, even if later the wound was closed, the scar could be pronounced (Fig).

Experimental example 7: Application of bandages using properties bandages (method use by attaching polar groups to the hydrocarbon cotton fabric)

In the case of the manufacture and use of resins as type dressings, it is difficult to reuse such a resin as the agarose with a polar group, such as DEAE-cellulose. Because of the complex hydrocarbon resin with a substituent (derivationally difficult the first hydrocarbon) has a wide surface area and high ability to bind with proteins, the effect can be obtained when the resin is used by fixing it in the bandage in the form of a gel. However, it has the disadvantage of high cost. To compensate for this problem, it can also be used by attaching various polar groups and DEAE-groups 100% cotton fabric. Because chemically modified tissue are able to bind with protein, it has good elasticity, the fabric can be used by contact with the curved part of the body, and if the dissolved proteins effectively removed, it can be reused. The ability of a tissue to bind proteins slightly reduced compared with the resin for the purification of proteins, but the fabric can be different to use. Mainly individually selected treatment may be possible by further adding various drugs (e.g., disinfectant, antibiotic, antihistamine agent, steroid, and the like) and various lipids (e.g., ceramide, phospholipids, lipid mixtures and the like) on the recommendation of a physician. When it is made in the form of service, it can be expected that the fabric will be easy to use for the treatment of a patient suffering from atopic disease affecting the whole body.

The present invention relates to a method of easy manufacture of fabrics that can absorb proteins attached through the e DEAE-groups to cotton fabric.

A method of manufacturing a DEAE-cotton fabric according to the present invention is as follows:

1) drying cotton fabric after washing in distilled water;

2) immersing the dried thus cotton fabric in 3M NaOH for 30 seconds;

3) immersing the thus obtained cotton in a mixed solution of 3M NaOH and 3M DEAE-Cl (diethylaminoethylamine) for 40 minutes.

4) immersing the thus obtained cotton 3M DEAE-Cl;

5) washing the thus obtained cotton cloth with distilled water and

6) drying the thus obtained cotton fabric.

When DEAE-cotton fabric manufactured in a mass production scale, as described above, it is possible to use a method like the one described on Fig. More effective bandage can be produced cheaply, and thus, it can benefit many patients, because the authors have simplified the method of manufacture.

DEAE-cotton fabric produced using the method described above is brought into contact with the affected area of a patient with atopic disease for about 4 hours, and then the absorption sweaty proteins was confirmed.

Fig 21 illustrates DEAE-cotton fabric, in which the left side is predstavljaet a fabric in a state of drying, and the right side is a fabric in a state of hydration using distilled water before applying to the affected area.

As shown in Fig, plain cotton fabric and DEAE-cotton fabric was brought into contact with the affected area for 5 hours, respectively. After removal of the fabrics, cut the pieces of fabric the same size, and then confirmed the presence of the dissolved proteins using SDS-PAGE. You can confirm that cotton fabric with DEAE-group can absorb and then delete the exudation of blood proteins from the affected area; the effect was not significantly different from the effect of the bandage of the agar gel containing DEAE-cellulose.

Cotton fabric with DEAE-group or other polar groups, can be used for the treatment of atopic diseases, psoriasis and other similar diseases. In addition, it is expected that the above cotton fabric can be used for structural removal of waste from the skin. In some cases it can remove specific lipids or poorly water-soluble proteins by binding with octiles group, butilkoi group, etc. Respectively, in addition to the aim of the treatment, it can be used for cosmetic purposes (for example, as materials for cosmetic masks), and this item is it is cheap, and does not harm the environment, because it can be reused.

1. Bandage for the treatment of skin diseases or alleviate symptoms of skin diseases, in which there is exudation of blood proteins, and the bandage includes:
a) a polymer matrix with microsaccades structure and
b) polar resin to bind to the proteins contained in the matrix, and/or resin to bind to the proteins through hydrophobic binding.

2. Bandage for the treatment of skin diseases or alleviate symptoms of skin diseases according to claim 1, in which the polymer matrix with microsaccades structure represents microsaccade the structure of complex carbohydrate selected from the group consisting of agar and agarose, or microetching structure fabricated using polyacrylamide, latex, polystyrene, polyvinyl chloride, silicone, polyurethane or cellulose fibers.

3. Dressing for the treatment of skin diseases or alleviate symptoms of skin diseases according to claim 1, in which the polar resin is a agarose, Sephadex, or separate with DEAE (Diethylaminoethanol) group; agarose, Sephadex, or separate with CM (carboxymethyl) group; agarose, Sephadex, or separate with trimethylammonio group; a resin having a functional group, such as sulfonylurea derivatives or about spodnie sulfonic acid as S-cation exchange resin; or polar resin (loaded resin) of granules of hydroxyapatite or polystyrene patterns.

4. Bandage for the treatment of skin diseases or alleviate symptoms of skin diseases according to claim 1, in which the resin to bind to the proteins through hydrophobic binding (hydrophobic interaction)is a resin containing a hydrocarbon chain length from C4 to C10.

5. Bandage for the treatment of skin diseases or alleviate symptoms of skin diseases according to claim 1, where the dressing is made by placing in a specific order of resins with different polarities.

6. Bandage for the treatment of skin diseases or alleviate symptoms of skin diseases according to claim 1, where the skin disease includes atopic dermatitis, eczema, psoriasis, contact dermatitis, erythema, herpes, chronic or contact urticaria, nodular the prurigo of Hyde (prurigo nodularis) and a slight burn or scald with boiling water or steam, which does not damage the outer layer of the skin.

7. Bandage for the treatment of skin diseases or alleviate symptoms of skin diseases according to any one of claims 1 to 6, where the bandage further includes genesisone phospholipids, organic acids or divalent cations.

8. Bandage for the treatment of skin diseases or alleviate symptoms of skin diseases according to any one of claims 1 to 6, where the bandage further includes triacylglycerol, the Church is, ceramide derivatives, complex lipids extracted from animals, or synthetic lipids.



 

Same patents:
Burn ointment // 2523551

FIELD: medicine.

SUBSTANCE: ointment contains biologically active substances which are Apis mellifera in an amount of 21-23 wt %, St. John's wort oil in an amount of 12-14 wt %, propolis in an amount of 10-12 wt % and wax in an amount of 7-9 wt %, as well as Vaselin and lanolin as the ointment base.

EFFECT: invention accelerates cell regeneration processes considerably due to a synergetic action of the ingredients.

7 ex

FIELD: medicine.

SUBSTANCE: method involves coating a keratoma surface with a mixture of meadow saffron tincture 1 table spoon and Phellinus tuberculosus tincture 3-4 drops. The mixture is applied once a day on the keratoma and a skin area 1.5-2.0 mm from the keratoma border. The mixture is applied by a thin brush, first with a prime layer and with a second layer after drying.

EFFECT: minimally painful keratoma removal.

3 ex

FIELD: medicine.

SUBSTANCE: material consists of several layers: an inner layer is made from chitosan nanofibres/superfine fibres, and an outside layer are used as an electrical forming substrate and exercise the protective function. The chitosan layer is made from herbal or mixed herbal and animal chitosan and can contain antibiotic. The multilayer material can contain at least one more layer of biopolymer nanofibres/superfine fibres electroformed of cellulose diacetate or gelatin. The three-layer material with the chitosan layer of the nanofibres/superfine fibres is applicable for local wound and burn healing.

EFFECT: material resistance to mechanical stress.

15 cl, 4 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dermatology and may be used for stimulating repair of wounds of various geneses. For this purpose, wound cleansing is followed by daily dressings with dihydroquercetin powder applied on a wound surface at the bacterial content no more than 103-4 m.c. per 1 cm2 as a layer of 1-2 mm until wound self-epithelisation, before or after autodermoplasty with a free split-skin flap. That is combined with prescribing the biologically active additive Laviocard+ orally 1 capsule 2 times a day with food for 21 day.

EFFECT: method provides correcting abnormal lipid peroxidation and activating antioxidant protection in local and systemic homeostasis by stimulating and reducing a repair length.

2 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: invention can be used for treating degree III-IV radiation injuries on radiation fields following neutron therapy in patients suffering from local recurrent breast cancer (BC). That is ensured by wound irrigation with ozonised distilled water with ozone concentration of 10,000 mcg/l; a skin ulcerous defect is processed in a vacuum container for 10-15 minutes with gaseous ozone with the concentration of 10,000 mcg/l. That is followed by ozonised air applications with the parameters of: peroxide number - 18%, acid number - 71 mg CFU/g on the skin ulcerous defect once or twice a day for 10-15 days every 5-7 days for 2-3 courses.

EFFECT: ulcer detersion from purulent deposits, active regeneration and the skin ulcerous defect healing.

6 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and may be used for treating an individual suffering from a persistent, sluggish, partially healing, open or chronic wound. That is ensured by administering anti-connexin 43 polynucleotide approximately 0.001 to approximately 1 mg/kg of body weight into the wound of the individual in a pharmaceutically acceptable carrier. Stimulating and improving wound healing, improving wound healing rate in a diabetic patient and an individual suffering from a chronic skin wound is also suggested. Kits and finished products containing Pluronic F-127 and anti-connexin 43 polynucleotide presented by SEQ ID NO: 1 for wound healing.

EFFECT: group of inventions provides wound healing, relieved inflammation within the persistent wound, as well as minimised cicatrisation.

129 cl, 4 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using a compound of formula (1) or its salt for preparing a drug for increasing HIF-1α stabilisation in a cell, as well as for preparing a drug enhancing the immune response in an individual, for preventive management of a wound to avoid an infection, for treatment of the microbial infection, for improvement of efficacy of a vaccine for management of the wound in the individual. What is presented is a pharmaceutical composition containing the above HIF-1α prolyl hydroxylase inhibitor and one or more additives. What is shown is achieving the declared applications by using the new compound of formula (1) with the HIF-1α prolyl hydroxylase (HIFPH2 (EGLN1)) inhibitor. It makes it applicable for treating HIF-1 alpha activity related diseases, conditions and/or syndromes.

EFFECT: preparing the drug for increasing HIF-1α stabilisation in a cell.

26 cl, 20 dwg, 8 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: invention refers to the veterinary science, particularly to substances used in treating purulent-necrotic involvements of bovine's distal extremities, including digital dermatitis. A preparation for treating bovine digital dermatitis in the form of an ointment consists of an excipient, containing an ointment base, and an active ingredient - zinc oxide and copper sulphate in the following proportions, wt %: zinc oxide 9-11, copper sulphate 35-45, the ointment base - the rest.

EFFECT: invention provides higher clinical effectiveness with cost cutting for the ointment preparation.

1 tbl

FIELD: chemistry.

SUBSTANCE: composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water.

EFFECT: providing a composition which stimulates a reparative process in external protective tissue, having anti-inflammatory and radioprotective action.

1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: group of inventions relates to the field of biotechnology. Claimed is a method of purification of a factor, contributing to wound healing, which represents a hepatocyte growth factor (HGF). All stages of purification are carried out in the presence of antithrombin III (AT-III). In accordance with the claimed method carried out are: defrosting of the frozen HGF-containing source and removal of sediment from the defrosted source. After that, the obtained solution, which contains a supernatant and AT-III, is brought in contact with a carrier for affinity chromatography on an immobilised heparin. Then, the solution is separated from the carrier for affinity chromatography. The carrier is brought in contact with a desorption buffer with ionic strength sufficient for HGF desorption. The desorption buffer, containing HGF, AT-III and histidine-rich glycoprotein (HRGP) is collected. Also claimed are wound-healing compositions, which contain HGF, AT-III and/or HRGP, purified by the claimed method.

EFFECT: inventions make it possible to increase step-by-step output of the hepatocyte growth factor, with the hepatocyte growth factor being concentrated in eluate in the presence of AT-III.

26 cl, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: material consists of several layers: an inner layer is made from chitosan nanofibres/superfine fibres, and an outside layer are used as an electrical forming substrate and exercise the protective function. The chitosan layer is made from herbal or mixed herbal and animal chitosan and can contain antibiotic. The multilayer material can contain at least one more layer of biopolymer nanofibres/superfine fibres electroformed of cellulose diacetate or gelatin. The three-layer material with the chitosan layer of the nanofibres/superfine fibres is applicable for local wound and burn healing.

EFFECT: material resistance to mechanical stress.

15 cl, 4 dwg, 8 ex

FIELD: packaging industry.

SUBSTANCE: invention relates to a package in which the adhesive tape is packaged, which has a layer of adhesive agent on the substrate. The package 10 for the self-adhesive adhesive tape comprises the adhesive tape 14 having a substrate 18 and the adhesive agent layer 12, provided on one surface of the substrate 18, and comprises a release sheet 16 is attached with the ability to release to the adhesive agent layer 12. The release sheet 16 is folded along a predetermined fold line with the adhesive tape 14 so that the adhesive agent layer faces outwardly and the folded adhesive tape 14 is sealed inside the folded release sheet 16.

EFFECT: according to this configuration, the traditionally occurring package separate from the release sheet can be eliminated; moreover, when the release sheet 16 is opened as detaching of the release sheet 16 from the adhesive agent layer 12 of the adhesive tape 14, half of the adhesive agent layer 12 is opened making the process of applying to the area for applying simple.

18 cl, 15 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine. Described is a composition for transcutaneous delivery, in particular, ionophoretic transcutaneous delivery of at least one cationic active substance or its salt, with the composition containing the said at least one cationic active substance or its salts, at least one polyamine and/or polyamine salt, water or water dissolving mixture and optionally one or several additives.

EFFECT: described is application of the claimed composition as a component of transcutaneous plaster or ion-phoretic transcutaneous plaster and application of the claimed composition in a method of transcutaneous or ionophoretic introduction of cationic active substances and in a method of determining in vitro properties of permeability through the skin, containing an active substance of the ionophoretic composition.

26 cl, 1 tbl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and can be used in need of the delivery of therapeutic compositions for local application, including for local analgesic therapy. That is ensured by a system comprising a container having a first chamber with a therapeutic composition for local application with at least one active ingredient, and a second chamber containing a coating composition. The composition for local application and the coating composition is dispensed through a valve and supplied through one nozzle gradually. The delivery can be also gradual by dispensing the composition for local application by pressing a first release button, while the coating composition is dispensed from the system by pressing a second release button.

EFFECT: invention provides the most convenient delivery of the therapeutic compositions ensured by the gradual release of the two compositions having different consistence through the same nozzle.

22 cl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and represents a self-degradable transdermal therapeutic system (TTS) containing at least one active ingredient, at least one agent disabling the active substance with the agent representing a solid substance or a paste, at least one release agent between the active substance and the agent disabling the active substance; the release agent represents a liquid-permeable and solid-impermeable layer, a mobile phase and at least one mechanical agent for perforating at least one adjacent layer of the TTS; the perforation agent has a dull outline and an acute or pointed area inside; when the TTS is released after the use, the perforation agent degrades the release agent between the release agent and the agent disabling the active ingredient thereby it enables the mobile phase supplied onto the agent disabling the active ingredient and enabling the contact of the active ingredient with the agent disabling the active ingredient, while the active ingredient is degraded by this contact.

EFFECT: device enables reducing a risk of undesired release of the preparation in transportation, provides the prolonged storage.

12 cl

FIELD: medicine.

SUBSTANCE: invention represents a composition for the topical delivery of a composition containing a nitrogen oxide donor specified in L-arginine or its derivative; an adverse biophysical medium containing an ionic salt; a stabilisation polymer containing xantham gum; propylene glycol; a polysorbate surfactant containing Polysorbate 20; and ibuprofen and/or an ibuprofen salt, to the individual's skin.

EFFECT: creating the composition possessing temperature stability at high temperatures.

20 cl, 1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Transdermal medication, which applies intensifier of percutaneous suction, is described. Intensifier of percutaneous suction has ester of sulfosuccinate in its composition or its salt and alkylglycoside or alkylthioglycoside.

EFFECT: described is intensifier of percutaneous suction, which has excellent action of percutaneous suction amplification for broad range of medications, demonstrating at the same time excellent compatibility with substances of glue base.

13 cl, 15 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. There are described compositions for percutaneous administration of physiologically active agents such as drugs or veterinary agents, including a hydrophobic polymer and a solvent.

EFFECT: compositions are characterised by the ultra-high prolonged efficacy ensured by their ability to form the stable skin films.

12 cl, 20 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmaceutical compositions for treating urination disturbance that is a syndrome manifested by frequent urination, urinary incontinence, urine retention, etc. The pharmaceutical composition contains an anticholinergic preparation that is diphenyl-acetic acid tropine ester, and preparations of the other mode of action, including Tamsulosin hydrochloride or calcium channels or baclofen in the form of prolonged release tablets or capsules or transdermal dosage forms (gels, ointments or plasters).

EFFECT: using the invention enables extending the range of therapeutic agents and improving the clinical effectiveness in urination disturbances accompanying a variety of common urological, neurological and gynaecological conditions alongside with improving the quality of life in patients with the urination disturbance.

4 cl, 24 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, namely it represents a rapidly dissolved or short lived preparation of a film containing a large number (i.e., at least about 40%) of the active material(s), and methods for preparing it. The invention represents a rapidly dissolved or short lived dry film for active substance delivery, containing an active substance, one water-soluble polymer specified in pullulan, hydroxypropylmethyl cellulose, polyvinylpyrrolidone and mixtures thereof, and other optional ingredients.

EFFECT: implementing the use of the invention provides creating the orally available preparations containing a great portion of the active substances.

10 cl, 10 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is an antimicrobial and wound healing agent of hydrogel polymeric matrix used for wounds, burns and dermatologic disorders. The agent has the following formulation, wt %: polyvinylpyrrolidone - 2-10, agar - 1, polyethylene oxide - 1-3, an antimicrobial pharmaceutical substance selected from gentamycin and miramystine - 0.02-1,0, water - the rest. The agent is prepared by cross-linking medical polymers under ionising radiation. The hydrogel polymeric matrixes of the various area are sterile and ready for application on open wound surfaces.

EFFECT: agent exhibits elasticity, breaking strength, sorption properties in relation to wound exudate, transparency that enables following a course of wound process, painless removal from wound surface, creates an optimum microclimate in a wound (humidity, temperature).

3 cl, 3 ex

Up!